Loading…
Immunome, Inc. is projected to rise to $27.82 by 2027, a +26% move from its current price of $22.11. IMNM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $21.44 | $22.12 | $22.83 | +0.06% |
| May 30 | $21.17 | $22.14 | $23.14 | +0.11% |
| May 31 | $20.98 | $22.15 | $23.38 | +0.17% |
| Jun 1 | $20.81 | $22.16 | $23.59 | +0.23% |
| Jun 2 | $20.67 | $22.17 | $23.78 | +0.28% |
| Jun 3 | $20.54 | $22.19 | $23.96 | +0.34% |
| Jun 4 | $20.43 | $22.20 | $24.12 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $20.43 | $22.20 | $24.12 | +0.40% |
| Week 2 | $19.82 | $22.29 | $25.06 | +0.79% |
| Week 3 | $19.38 | $22.37 | $25.83 | +1.19% |
| Week 4 | $19.03 | $22.46 | $26.52 | +1.60% |
| Week 5 | $18.73 | $22.55 | $27.15 | +2.00% |
| Week 6 | $18.48 | $22.64 | $27.74 | +2.40% |
| Week 7 | $18.25 | $22.73 | $28.31 | +2.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immunome, Inc. is a biotechnology company that engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Its clinical assets comprise Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Immunome is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Immunome, Inc. (IMNM) is a biotechnology company with a current price of $21.66.
Its market capitalization is $2.45B and it is ranked 1871.
The price outlook is bullish over the long horizon, with the forecast showing the average price rising from $21.66 in 2026 to higher levels by 2050, with notable steps along the way such as 2027 avg $28.83 and 2040 avg $133.98, culminating in 2050 avg $210.59.
A major floor 22.4% below — a decisive break under it would weaken the trend.
The nearest floor, 11.1% below — buyers have tended to step in here.
The nearest ceiling, 11.4% above — a clean break opens room to run.
A major ceiling 22.6% above — clearing it would confirm fresh momentum.
Key IMNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.03 | Buy | $21.86 | Buy |
| MA 10 | $21.48 | Buy | $21.83 | Buy |
| MA 20 | $22.17 | Sell | $22.04 | Buy |
| MA 50 | $22.07 | Buy | $22.14 | Sell |
| MA 100 | $22.37 | Sell | $21.43 | Buy |
| MA 200 | $18.59 | Buy | $19.18 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.92 | Neutral |
| Stoch RSI (14) | 80.42 | Sell |
| CCI (20) | -5.53 | Neutral |
| Williams %R (14) | -26.65 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -1.47 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 73.35 | Neutral |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | -0.61 | Sell |
| Ultimate (7,14,28) | 53.48 | Neutral |
| Momentum (10) | -0.58 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 22.44 | Sell |
| ADX (14) | 11.79 | Neutral |
| ATR (14) | 0.64 | Info |
The 30-day technical picture is bullish. RSI14 is 50 and the momentum is supported by a SMA50 of $22.01 alongside a SMA200 of $18.47.
Near-term levels place support at $19.66 and resistance at $24.63, with the 30-day price range spanning from $17.40 to $26.97.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.30 | $22.11 | $28.74 | 0% | Neutral | |
| $21.75 | $27.82 | $37.89 | +26% | Bullish | |
| $28.71 | $37.91 | $53.74 | +71% | Bullish | |
| $29.24 | $39.65 | $58.01 | +79% | Bullish | |
| $31.40 | $43.60 | $65.52 | +97% | Bullish | |
| $32.78 | $46.53 | $71.56 | +110% | Bullish | |
| $32.56 | $47.16 | $74.06 | +113% | Bullish | |
| $38.25 | $56.48 | $90.39 | +155% | Bullish | |
| $44.67 | $67.17 | $109.39 | +204% | Bullish | |
| $48.64 | $74.44 | $123.20 | +237% | Bullish | |
| $69.21 | $114.80 | $203.27 | +419% | Bullish | |
| $93.47 | $178.64 | $348.80 | +708% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $19.30 | $22.11 | $25.96 | +0.00% |
| June 2026 | $19.08 | $22.47 | $27.16 | +1.65% |
| July 2026 | $19.57 | $23.28 | $28.57 | +3.58% |
| August 2026 | $19.01 | $22.79 | $28.31 | -2.09% |
| September 2026 | $18.38 | $22.17 | $27.79 | -2.75% |
| October 2026 | $18.71 | $22.70 | $28.71 | +2.41% |
| November 2026 | $18.84 | $22.97 | $29.27 | +1.18% |
| December 2026 | $18.27 | $22.39 | $28.74 | -2.51% |
Click any year to see its month-by-month IMNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMNM could reach as high as $28.74, with a base case around $22.11 and support toward $19.30 — roughly 0% from $22.11. Price action looks broadly range-bound.
Expect IMNM to range from $21.75 to $37.89 through 2027. The $27.82 average target implies a +26% move from current prices. That is up +26% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The IMNM price prediction for 2028 points to an average of $37.91 (low $28.71, high $53.74) — a potential gain of +71% on today's $22.11. Momentum favours further upside here.
In 2029, IMNM is projected to trade between $29.24 and $58.01, averaging $39.65 — a potential gain of +79% from today's $22.11. That is up +5% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Immunome, Inc.'s 2030 outlook centres on $43.60, within a $31.40 to $65.52 range. That is up +10% on the projected 2029 average. That marks a +97% change versus current levels. Momentum favours further upside here.
By 2031, IMNM could reach as high as $71.56, with a base case around $46.53 and support toward $32.78 — roughly +110% from $22.11. Buyers look set to stay in control over this stretch.
Expect IMNM to range from $32.56 to $74.06 through 2032. The $47.16 average target implies a +113% move from current prices. That is up +1% on the projected 2031 average. Momentum favours further upside here.
The IMNM price prediction for 2033 points to an average of $56.48 (low $38.25, high $90.39) — a potential gain of +155% on today's $22.11. Buyers look set to stay in control over this stretch.
In 2034, IMNM is projected to trade between $44.67 and $109.39, averaging $67.17 — a potential gain of +204% from today's $22.11. That is up +19% on the projected 2033 average. Momentum favours further upside here.
Immunome, Inc.'s 2035 outlook centres on $74.44, within a $48.64 to $123.20 range. That is up +11% on the projected 2034 average. That marks a +237% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, IMNM could reach as high as $203.27, with a base case around $114.80 and support toward $69.21 — roughly +419% from $22.11. Momentum favours further upside here.
Expect IMNM to range from $93.47 to $348.80 through 2050. The $178.64 average target implies a +708% move from current prices. That is up +56% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMNM today (≈ 45.228403 IMNM) could be worth
$8,079.4
+$7,079.4 (+708%) by 2050 · US Dollar
Based on the average projected IMNM price of $178.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMNMwould be worth at today's price.
$1,000 invested in IMNM on May 27, 2025 (≈ 116.279065 IMNM) would be worth
$2,570.93
+$1,570.93 (+157.1%) today · 2.57× · US Dollar
Based on a IMNM entry price of $8.6 vs. today's $22.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.53 | $1,026.94 | +2.7% |
| 1 month ago | $23.49 | $941.25 | -5.9% |
| 3 months ago | $21.89 | $1,010.05 | +1.0% |
| 6 months ago | $18.42 | $1,200.33 | +20.0% |
| 1 year ago | $8.6 | $2,570.93 | +157.1% |
| All time (5.0y) ago | $20.58 | $1,074.34 | +7.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMNM forecast.
Our base-case forecast reaches $44.00 around 2031.
Implied market cap at $44.00: $4.98B
The multi-year forecast shows a bullish trajectory with rising average prices and higher ROI across the horizon. In 2026, the avg is $21.66 with ROI 0 and sentiment NEUTRAL. The path strengthens in following years: 2027 avg $28.83 with ROI 33.1, 2028 avg $39.89 with ROI 84.1, and 2029 avg $41.57 with ROI 91.9, all with bullish sentiment.
By 2030 the avg is $46.69 with ROI 115.6 and sentiment BULLISH. By 2040 the avg is $133.98 with ROI 518.5 and sentiment BULLISH, and by 2050 the avg is $210.59 with ROI 872.2 and sentiment BULLISH.
Additional years show continued growth: 2031 avg $50.13; 2032 avg $50.92; 2033 avg $63.35; 2034 avg $75.60; 2035 avg $83.59, all marked with bullish sentiment. These are estimates, not guarantees, and actual results depend on future conditions.
Tap a question to reveal the answer.
Avg $46.69; Min $33.19; Max $71.15; ROI 115.6; sentiment BULLISH.
The forecast shows sentiment BULLISH for 2027–2050 with rising Avg prices (e.g., 2027 avg $28.83; 2028 avg $39.89; 2029 avg $41.57) and positive ROI (33.1 in 2027, 84.1 in 2028, 91.9 in 2029). The 2026 forecast is neutral with avg $21.66 and ROI 0.
Yes. The forecast shows 2040 avg $133.98 and 2050 avg $210.59, with 2040 min $78.60 and max $242.17 and ROI 518.5.
Current price $21.66; market cap $2.45B.
Avg $210.59; Min $105.78; Max $421.26; ROI 872.2; sentiment BULLISH.
Immunome, Inc. Community Discussion
0Share your Immunome, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.